Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with
CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response
and major molecular response rate) is dependent on the residual plasma Imatinib.